Portfolio Overview
The Healthcare Innovation Portfolio (ID 163) is a thematic portfolio focused on global healthcare technology. As of July 21, 2026, the portfolio holds seven positions, all within their minimum holding periods. No positions are recommended for closure this week.
Performance Highlights
- Inspire Medical Systems (INSP) leads with a +16.83% return since pick, driven by strong demand for its sleep apnea therapy and positive clinical data.
- Doximity (DOCS) continues its steady climb (+3.99%), benefiting from digital health adoption.
- TransMedics (TMDX) is slightly down (-1.58%) but remains a key player in organ transplant technology.
- Globus Medical (GMED) (-5.48%) and Butterfly Network (BFLY) (-6.19%) face near-term headwinds but maintain strong fundamentals.
- Procept BioRobotics (PRCT) (-6.23%) and NeoGenomics (NEO) (-2.63%) are recent adds with long-term potential in surgical robotics and precision diagnostics.
Risk and Concentration
The portfolio is concentrated in small- to mid-cap healthcare technology, which carries higher volatility. No single position exceeds 20% of the portfolio, mitigating idiosyncratic risk. The theme remains well-supported by secular trends in aging populations and technological advancement.
What to Watch
Key catalysts include upcoming earnings reports for INSP, TMDX, and GMED. Regulatory developments in AI-based diagnostics and robotic surgery could impact BFLY and PRCT. We remain disciplined and will reassess positions as they approach their minimum holding periods.
Disclaimer: This is not investment advice. Past performance is not indicative of future results. All investments carry risk, including loss of principal. Consult a financial advisor before making investment decisions.